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Coronavirus disease 2019 (COVID-19) is a disease caused 
by infection with the SARS-CoV-2 virus, which in 
January 2020 began to spread from Wuhan around the 
world (Hui et al., 2020). Globally, on August 30th 2020, 
there have been 24,854,140 confirmed cases of COVID-19, 
including 838,924 deaths (World Health Organization, 
2020). One of the targets that have become a focus of 
research in the world for COVID-19 therapy was SARS-
CoV-2 main protease (MPro) (Dai et al., 2020; Jin et al., 2020; 
Wu et al., 2020; Zhu et al., 2011). The main protease is a key 
enzyme in the viral replication cycle, which 
proteolytically cleaves overlapping polyproteins pp1a 
and pp1ab into functional proteins, an essential step 
during viral replication (Du et al., 2004). Inhibition of these 
target proteins can result in disruption of the SARS-CoV-
2 replication cycle (Mahmud et al., 2020; Pratama et al., 
2020). The SARS-CoV-2 MPro in COVID-19 is not the 
same as the main protease in humans, so it becomes a 
promising therapeutic target (Ullrich & Nitsche, 2020). 
Many compounds derived from medicinal plants have 
not been discovered and have great potential as 
therapeutic candidates (Mushtaq et al., 2018; Pan et al., 
2013). In the discovery of COVID-19 therapy candidates, 
many natural products were used; some of them 
examined compounds from herbs against the SARS-
CoV-2 using in silico method (Aanouz et al., 2020; 
Enmozhi et al., 2020; Joshi et al., 2020; Prasanth et al., 2020; 
Sukardiman et al., 2020). However, the discovery of 
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The COVID-19 pandemic has become a serious problem today, with 
its prevalence increasing every day. The SARS-CoV-2 main protease 
(MPro) is a promising therapeutic target to inhibit replicating and 
spreading the virus that causes COVID-19. The compounds contained 
in the Etlingera elatior plant has the potential. This study aimed to 
examine the compounds' activity in E. elatior against SARS-CoV-2 MPro 
using in silico methods. A total of seven compounds contained in E. 
elatior were obtained from the Knapsack database. The compounds 
were then docked into the SARS-CoV-2 MPro receptor's active site with 
the PDB ID 6LU7. Afterward, the biological activities were predicted 
by the PASS prediction webserver. The molecular docking results 
showed that ergosterol peroxide and sitostenone had the best binding 
energy with -10.40 kcal/mol and -9.17 kcal/mol, respectively. The in 
silico PASS prediction showed it has potential as antiviral therapy. It 
concluded ergosterol peroxide and sitostenone has the potential as 
SARS-CoV-2 MPro inhibitor candidate. 
 
Received: August 30th, 2020 
Accepted: October 24th, 2020 
Published: November 30th, 2020 
   
 
© 2020 Dwi Syah Fitra Ramadhan, Taufik Muhammad Fakih, Arfan. Published by Institute for Research and 
Community Services Universitas Muhammadiyah Palangkaraya. This is an Open Access article under the CC-BY-
SA License (http://creativecommons.org/licenses/by-sa/4.0/). DOI: https://doi.org/10.33084/bjop.v3i4.1634 
 
Research Article 
Borneo Journal of Pharmacy, Vol 3 Issue 4, November 2020, Page 235 – 242  e-ISSN: 2621-4814 
236 
compounds from medicinal plants with potential activity 
as SARS-CoV-2 MPro inhibitors is still being carried out 
today. 
Etlingera elatior (known as Wualae in Tolakinese) is a 
medicinal plant from Indonesia which are found mainly 
on the island of Sulawesi, particularly Southeast Sulawesi 
(Fristiohady et al., 2020; Fristiohady et al., 2019). Etlingera 
elatior contains various types of compounds, including 
flavonoids and steroids with various pharmacological 
activities, one of them as antimicrobial (Sahidin et al., 
2019; Wahyuni et al., 2018). However, there has been no 
specific development of its antiviral activity until now, 
especially to the SARS virus family. Flavonoid and 
steroid group compounds as found in E. elatior have been 
widely researched on their activity to the SARS-CoV-2 
and have shown promising results as a drug candidate 
for COVID-19 (Islam et al., 2020; Suwannarach et al., 2020). 
Therefore, this study aims to identify compounds from 
the flavonoid and steroid group contained in E. elatior, 
which have potential as SARS-CoV-2 MPro inhibitors. 
 
MATERIALS AND METHODS 
Ligand preparation 
The ligands used in this study were compounds 
contained in E. elatior. A total of seven compounds 
contained in E. elatior were selected in this study based on 
the KNApSAcK database 
(http://www.knapsackfamily.com/KNApSAcK/) 
(Afendi et al., 2012). The compound identity, as well as 
their two-dimensional structure, can be seen in Table I. 
The three-dimensional ligand conformation was 
obtained from the KNApSAcK 3D database 
(http://knapsack3d.sakura.ne.jp/) (Nakamura et al., 
2013). The compounds saved in .mol format, then 
converted into .pdb format using the OpenBabel 2.4.1 
GUI software. 
 
Table I. Identity of the compounds contained in E. elatior 




Compounds 2D structure 











4 C00005373 Isoquercetin 
 












The three-dimensional structure of the SARS-CoV-2 MPro 
was obtained from the Protein Data Bank (PDB) website 
http://www.rcsb.org/pdb/. The receptor with the PDB 
ID 6LU7 and resolution 2.16 Å was chosen. Furthermore, 
the unique ligands and water molecules were removed 
from the receptor. Then, the receptor was added with 
polar hydrogen and given a charge (Kollman charge). All 
preparation procedures were performed using 
AutoDock 4 software (Morris et al., 2009). 
Validation method 
The native ligand from the 6LU7 receptor (N-[(5-
methylisoxazol-3-yl)carbonyl]alanyl-l-valyl-N~1~-
((1R,2Z)-4-(benzyloxy)-4-oxo-1-{[(3R)-2-oxopyrrolidin-3-
yl]methyl}but-2-enyl)-l-leucinamide; an inhibitor N3) (Jin 
et al., 2020) was separated from the protein, then re-
docked using AutoDock 4 software into the previous 
active site. The native ligand conformation from the 
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docking procedure was taken and overlayed with the 
native ligand conformation before docking. 
Furthermore, validation is done by looking at root-mean-
square deviation (RMSD) parameters, calculated using 
PyMOL software. An RMSD value of fewer than 2.0 Å 
indicates that the method is valid and can be used for the 
docking process (Bell & Zhang, 2019). 
Molecular docking simulation 
The simulation was carried out using previously valid 
parameters. The three-dimensional structure of the 
compounds in E. elatior was docked to the SARS-CoV-2 
MPro receptor's active site, which is then analyzed for its 
binding energy and amino acid interactions. The active 
site coordinates were x=-9.732, y=11.403, and z=68.925, 
with the dimensions of the grid box, were 64, 60, and 60 
Å, respectively. The docking process in AutoDock 4 has 
been performed with 100 number of GA runs for each 
ligand. 
Prediction of Activity Spectra for Substances 
The in silico Prediction of Activity Spectra for Substances 
(PASS) were carried out to get biological activity spectra 
of compounds accessed through PASS web server 
(http://www.way2drug.com/PASSOnline/predict.ph
p) (Marwaha et al., 2007). This server estimates the 
predicted activity spectrum of a compound as probable 
activity (Pa) and probable inactivity (Pi). Prediction of this 
spectrum by PASS is based on structure-activity 
relationship analysis of the training set containing more 
than 205,000 compounds exhibiting more than 3,750 
kinds of biological activities. For probabilities range, the 
Pa and Pi values vary from 0.000 to 1.000. The PASS 
prediction results were interpreted and used flexibly: 
1. Only activities with Pa > Pi are considered as possible 
for a particular compound. 
2. If Pa >0.7, the chance to find activity is experimentally 
high. 
3. If Pa is >0.5 but less than <0.7, the chance to find 
activity is experimentally low, but the compound is 
probably different from known pharmaceutical 
agents. 
4. If Pa <0.5, the chance to find activity is experimentally 
is low, but the chance to find structurally NCE’s is 
high. 
 
RESULTS AND DISCUSSION 
Validation method 
Validation was carried out to see the strength of affinity 
prediction through re-docking the native ligand into its 
binding site. The validation results can be seen in Figure 
1. It showed that the RMSD value of the native ligand 
was 1.3 Å, with the binding energy obtained was -7.30 
kcal/mol. This shows that the molecular docking 
method used is valid because of the RMSD value below 
2.0 Å. 
 
Figure 1. Validation of the SARS-CoV-2 MPro receptor PDB ID 
6LU7, the native ligand position before docked (red) and after 
docked (blue) overlayed with RMSD 1.3 Å 
 
Molecular docking simulation 
The bioactive compounds in E. elatior after docked 
showed varied binding energies as shown in Table II. In 
general, E. elatior compounds from the database were 
dominated by polyphenols such as flavonoids and 
phenylpropanoid, then the steroid compounds. The 
flavonoid compounds such as quercetin, curcumin, etc., 
have been previously studied in silico against the SARS-
CoV-2 MPro receptor, as Cherrak et al. (2020) reported. 
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Meanwhile, the type of steroid has been previously 
studied by Ghosh et al. (2020). As shown by the docking 
results in Table II, the steroid group showed better 
inhibitory activity than the flavonoid groups to SARS-
CoV-2 MPro receptor. The docking results show that the 
steroids' binding energy, namely ergosterol peroxide and 
sitostenone, was -10.4 and -9.17 kcal/mol, respectively. 
Compared to the flavonoid group, the lowest binding 
energy was shown by catechins (-8.64 kcal/mol), while 
the binding energy of the other compounds was in the 
range of -6.53 to -7.9 kcal/mol. 
Table II. The binding energy of the compounds in E. elatior 















Flavonoid −7.08 6,450 
Isoquercetin Flavonoid −7.09 6,310 
Sitostenone Steroid −9.17 188.59 
Ergosterol peroxide Steroid −10.4 23.62 
Demethoxycurcumin Polifenol −7.9 1,630 
 
Molecular interactions 
The top two compounds that ranked by their binding 
energy, ergosterol peroxide and sitostenone, were 
analyzed for their amino acid interactions with the SARS-
CoV-2 MPro receptor and compared with the interactions 
of the native co-crystal ligand (N3 inhibitor). The 
interactions' tabulation data can be seen in Table III, 
while the two-dimensional interaction can be seen in 
Figure 2. The native ligand forms hydrogen bonds with 
amino acids Gly-143; Cys-145; Glu-166; Gln-189; and Thr-
190. The native ligand also forms several types of 
hydrophobic interactions with residues His-41; Met-49; 
Met-165; Leu-167; Pro-168; and Ala-191, while the rest 
were Van der Waals interactions with ten residues. The 
steroid sitostenone forms a hydrogen bond with the 
amino acids Gln-192. Ergosterol peroxide forms 
hydrogen bonds with Thr-26 and Gly-143. Sitostenone 
forms hydrophobic interactions with six amino acid 
residues Leu-27; His-41; Met-49; Cys-145; His-163; and 
Met-165, as well as Van der Waals interactions with 13 
other amino acid residues. Ergosterol peroxide 
compounds form hydrophobic interactions with five 
amino acid residues, specifically His-41; Met-49; Cys-145; 
Met-165; and Arg-188, and form Van der Waals 
interactions with ten other amino acid residues. Overall, 
the interaction on sitostenone is more similar to the 
interaction of native ligands with a similarity level of 
82.6% compared to ergosterol peroxide with 56.52%. 
The interaction pattern shows that the hydrophobic 
group on the ligands influences the SARS-CoV-2 MPro 
receptor's affinity. This is what causes the steroid class 
compounds to give good affinity for this molecular 
docking simulation. This is also related to the native 
ligand structure, an inhibitor of SARS-CoV-2 MPro, which 
is composed of several non-polar peptide groups. In 
terms of three-dimensional interactions (Figure 3), 
ergosterol peroxide does not occupy the protein's surface 
as large as the native ligand. However, the functional 
groups on its compounds bind to a larger hydrophobic 
region in the protein surface (brown area), and one 
oxygen group can interact in the polar region (blue area). 
Simultaneously, sitostenone compounds form a similar 
orientation to the native ligand in occupying the surface 
of the receptor's binding pocket. 
Table III. Amino acid interactions of native and test ligands 
Interaction residues 
N3 inhibitor (native ligand) Sitostenone Ergosterol peroxide 
Thr-24 - - 
Thr-25 - Thr-25 
Thr-26 Thr-26 Thr-26 
- Leu-27 Leu-27 
His-41 His-41 His-41 
Met-49 Met-49 Met-49 
- - Pro-52 
- - Tyr-54 
Phe-140 - - 
Leu-141 Leu-141 - 
Asn-142 Asn-142 Asn-142 
Gly-143 Gly-143 Gly-143 
Ser-144 Ser-144 - 
Cys-145 Cys-145 Cys-145 
His-163 His-163 - 
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His-164 His-164 His-164 
Met-165 Met-165 Met-165 
Glu-166 Glu-166 Glu-166 
Leu-167 Leu-167 - 
Pro-168 Pro-168 - 
Asp-187 - Asp-187 
Arg-188 Arg-188 Arg-188 
Gln-189 Gln-189 Gln-189 
Thr-190 Thr-190 - 
Ala-191 Ala-191 - 
Gln-192 Gln-192 - 
The similarity of interaction 









Figure 2. Two-dimensional interactions of native ligand (A), 








Figure 3. Three-dimensional interactions of native ligand (A), 
sitostenone (B), and ergosterol peroxide (C) to SARS-CoV-2 
MPro receptor 
 
Prediction of Activity Spectra for Substances 
The PASS prediction was carried out on native ligand, 
ergosterol peroxide, and sitostenone compounds to see 
and compare their probability level as COVID-19 
therapy (Table IV). The native ligand was predicted to 
have activity in severe acute respiratory syndrome 
treatment, 3C-like protease (Human coronavirus) 
inhibitor, protease inhibitor, and antiviral, with Pa value 
of 0.357; 0.358; 0.321; and 0.312, respectively.  However, 
ergosterol peroxide and sitostenone were only predicted 
to have antiviral activity with a Pa value of 0.418 and 
0.495, respectively. 
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Table IV. In Silico PASS Prediction results 
Ligands Activities prediction Pa Pi 
Native Severe acute respiratory 
syndrome treatment 
0.357 0.005 
3C-like protease (Human 
coronavirus) inhibitor 
0.358 0.006 
Protease inhibitor 0.321 0.008 
Antiviral 0.312 0.033 
Sitostenone Antiviral 0.495 0.026 
Ergosterol peroxide Antiviral  0.418 0.073 
 
CONCLUSION 
Compounds in E. elatior (ergosterol peroxide and 
sitostenone) showed potential as inhibitor candidates for 
the SARS-CoV-2 MPro receptor. Although the PASS 
server's in silico prediction does not show specific activity 
against the receptor like native ligand, the bioactive 
compounds were predicted to have potential as antiviral. 
Moreover, from the molecular docking simulation, 
ergosterol peroxide and sitostenone showed better 
affinity against SARS-CoV-2 MPro compared to flavonoid 
groups and the native ligand. 
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